MSMatthias Stechele

Matthias Stechele

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Matthias Stechele has a total of 103 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Extracellular matrix remodeling and immune reprogramming drive residual tumor progression of liver cancer after incomplete microwave ablation

    by Yu Liu, Yubei He, Nikolaus Berndt, Michael Mülleder, Kathrin Textoris‐Taube, Jing Guo, Matthias Stechele, Justus Ramtke, Shraga Nahum Goldberg, Lynn Jeanette Savic

    Although microwave ablation (MWA) constitutes an effective targeted treatment for liver cancer, the mechanisms driving high recurrence rates remain poorly understood. To elucidate these processes, we established an incomplete MWA (iMWA) model in rabbit VX2 tumors and conducted proteomic profiling of residual tumors at Days 3 (D3) and 14 (D14) postablation. By integrating genomic profiles from mouse radiofrequency ablation (RFA) models, we identified 81 and 92 upregulated proteins at D3 and D14, respectively. Functional enrichment analysis (STRING and Enrichr) revealed acute injury response and extracellular matrix (ECM) remodeling predominating at D3, then markedly declining by D14. Conversely, pathways associated with signal transduction, tumorigenesis, and immune pathways were substantially upregulated at D14. Specifically, protein–protein interaction (PPI) analysis revealed that macrophage remodeling and immune checkpoint networks are functionally coupled at D14 to orchestrate an immunosuppressive microenvironment. Stouffer analysis confirmed the shift from matrix remodeling at an early stage to late‐stage oncogenic signal transduction and immune suppression at progression. Overall, these findings characterize the dynamic mechanisms of postablation residual tumor growth and highlight potential therapeutic targets to inhibit protumorigenic pathways while enhancing antitumor immunity.

  • Cross-Cancer Circulating Proteins for the Prognosis of Primary and Metastatic Liver Cancer Treated with Local Ablation: Post Hoc Exploratory Analysis of the ESTIMATE Trial

    by Luigi Nardone, Elif Öcal, Lukas Salvermoser, Matthias Philipp Fabritius, Daniel Puhr-Westerheide, Matthias Stechele, Stefanie Corradini, Jens Ricke, Moritz Wildgruber, Marianna Alunni-Fabbroni, et al.

    A circulating three-protein panel predicted response and survival after liver ablation across patients with primary and metastatic cancers, providing a novel tool to refine patient selection for liver-directed therapies.


  • Open Access

    TCOF1 in extracellular vesicles predicts survival in patients with HCC treated with high-dose conformal radiotherapy

    by Daniel Puhr-Westerheide, Elif Öcal, Heidrun Hirner-Eppeneder, Stefanie Corradini, Lukas Salvermoser, Matthias Stechele, Najib Ben Khaled, Ignazio Piseddu, Moritz Wildgruber, Max Seidensticker, et al.

  • Open Access

    Hepatic radiofrequency ablation induces widespread cellular activation throughout the liver

    by Matthias Stechele, Justin Amadi, Lukas Salvermoser, Lorenzo Sperlich, Jonathan Monin, Daniel Khademi, Moritz Nikolaus Gröper, Muneeb Ahmed, Eithan Galun, Jens Ricke, et al.

    Objective: We investigated the extent of cellular, transcriptional, and translational activation throughout the liver following radiofrequency ablation (RFA). Materials and methods: RFA of the healthy liver was performed in two 8–10-week-old male C57/Bl6 mice, no/sham procedure in one. One and 7 days after, single-cell RNA sequencing (scRNAseq) was performed on distant, untreated liver to examine > 6,000 genes from normalized datasets of > 6,000 cells/sample, enabling identification of ten major cell populations. We defined cell-to-cell interactions by CellphoneDB and identified active pathways via STRING-db analysis with Markov clustering. Twelve distant liver lobe samples were homogenized on day 3 or day 6 after RFA/sham procedure for SomaLogic proteomic analysis (> 1,300 genes), subsequent STRING-db analysis, and assessment of cellular origin (PanglaoDB-2021). Results: CellphoneDB identified crosstalk among all ten populations with 4,658 and 4,218 receptor/ligand pairs, identified on day 1 and day 7 post-RFA, respectively. On day 1, 360 differentially expressed genes were identified; on day 7, 430. Activated genes distributed into 16 clusters, including 66 chemokines/cytokines, including Ccl2 and Ccl7; 57 immunomodulators, including Il6, Ctla4 and Pdcd1; and 54 growth factors, including Vegf, Hgf, Pdgf, and Fgf. Angiogenesis pathway genes were observed in endothelial cells and hepatocytes. Pdcd1 and Ctla4 were notably increased transiently in T cells. Proteomic analysis included 228/443 genes (51%) identified by scRNAseq; 73/228 proteins (32%) demonstrated 25% elevation over controls. Overall, 427 proteins were elevated, with 9/10 cell populations contributing to increased protein expression (odds ratio 4.9‒7.0). Conclusion: RFA diffusely activates cellular processes remotely from the ablation zone on both transcriptional and translational levels, altering tumorigenic and immunologic pathways simultaneously. Relevance statement: This study offers insights into liver tissue biology after RFA and provides a comprehensive picture of the molecular mechanisms put into motion by this procedure. A better understanding of these processes could provide a potential basis to develop specific biomarkers and effective adjuvant therapies following local tumor ablation. Key Points: RFA activates a multiplicity of hepatic cellular processes remotely from the ablation zone on a transcriptional and translational level. Single-cell RNA sequencing provides insights into widespread cellular origins of activated pro-immunogenic, pro-tumorigenic, and other pathways detected post-ablation. Consideration of the nature of this response may help achieve the clinical goals of adjuvant therapies and predictive biomarkers. Graphical


  • Open Access

    In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

    by Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, et al.

    Tumor recurrence after local tumor ablation, including high dose rate brachytherapy (HDR‐BT), represents a substantial challenge in hepatocellular carcinoma (HCC) treatment. This study aimed to investigate whether induced factors that appear in patient serum after HDR‐BT alter HCC growth in vitro , and whether this correlates with outcome. In total, 23 HCC patients [Barcelona clinic liver cancer (BCLC) stage A or B] were treated by HDR‐BT (1 × 15 Gy) and classified as responders in case of no progression within 6 months and no diffuse systemic progression within 2 years ( n = 12), or nonresponders with recurrence within 6 months and/or diffuse systemic tumor progression or extrahepatic disease within 2 years ( n = 11). Patient serum was obtained at baseline and 48 h postprocedure. Two hepatoma cell lines (Huh7, HepG2) were incubated for 72 h in the presence of 20% serum. BrdU incorporation was assessed for serum incubation at baseline and 48 h post‐HDR‐BT. BrdU incorporation post‐HDR‐BT compared to baseline was significantly elevated in nonresponders compared to responders for both Huh7 and HepG2. Likewise, confirmatory Cyclin E studies revealed different induction kinetics between a subset of representative responders and nonresponders in HepG2. Time to systemic progression (TTSP) in patients with increased BrdU incorporation was significantly shorter compared to patients with decreased BrdU incorporation after serum incubation. These data indicate that poor outcome following HDR‐BT is associated with increased measurable proliferation parameters of hepatoma cell lines in vitro after exposure to patient serum, offering insights into post‐treatment tumor biology and a potential biomarker of clinical outcome.

  • Open Access

    Factors influencing diagnostic yield and complication risk in computed tomography fluoroscopy-guided lung biopsies: a 10-year single-center study

    by Nabeel Mansour, Hannah Gildein, Frederik F. Strobl, Osman Öcal, Tobias Geith, Daniel Puhr-Westerheide, Matthias Stechele, Sinan Deniz, Muzaffer R. Ümütlü, Nicola Fink, et al.

    Factors influencing diagnostic yield and complication risk in computed tomography fluoroscopy-guided lung biopsies: a 10-year single-center study - Diagnostic and Interventional Radiology

  • Open Access

    Immune Modulation in Untreated, Contralateral Hepatic Metastases after Yttrium-90 Radioembolization of Microsatellite Stable Colorectal Cancer

    by Elif Öcal, Marianna Alunni-Fabbroni, Ignazio Piseddu, Matthias Thaler, Mathias J. Zacherl, Lukas Salvermoser, Matthias M.R. Stechele, Lu Fornés Burnell, Heidrun Hirner-Eppeneder, Melanie A. Kimm, et al.


  • Open Access

    CT-guided high dose rate brachytherapy can induce multiple systemic proteins of proliferation and angiogenesis predicting outcome in HCC

    by Lukas Salvermoser, Shraga Nahum Goldberg, Marianna Alunni-Fabbroni, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Jan Niklas Schäfer, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, et al.


  • Open Access

    Circulating miR-21 as a prognostic biomarker in HCC treated by CT-guided high-dose rate brachytherapy

    by Matthias Stechele, Henrike Link, Heidrun Hirner-Eppeneder, Marianna Alunni-Fabbroni, Moritz Wildgruber, Lukas Salvermoser, Stefanie Corradini, Regina Schinner, Najib Ben Khaled, Daniel Rössler, et al.

    Background and aims: Prognostic biomarkers identifying patients with early tumor progression after local ablative therapy remain an unmet clinical need. The aim of this study was to investigate circulating miR-21 and miR-210 levels as prognostic biomarkers of HCC treated by CT-guided high-dose rate brachytherapy (HDR-BT).Materials and Methods: 24 consecutive HCC patients (BCLC A and B) treated with CT-guided HDR-BT (1 × 15 Gy) were included in this prospective IRB-approved study. RT-PCR was performed to quantify miR-21 and miR-210 levels in blood samples acquired prior to and 2 d after HDR-BT. Follow-up imaging (contrast-enhanced liver MRI and whole-body CT) was performed in 3 months follow-up intervals. Therapy response was assessed with patients classified as either responders or non-responders (12 each). Responders were defined as having no local or diffuse systemic progression within 6 months and no diffuse systemic progression exceeding 3 nodules/nodule diameter > 3 cm from 6 months to 2 years. Non-responders had recurrence within 6 months and/or tumor progression with > 3 nodules or individual lesion diameter > 3 cm or extrahepatic disease within two years, respectively. Biostatistics included parametric and non-parametric testing (Mann–Whitney-U-test), as well as Kaplan–Meier curve construction.Results: The responder group demonstrated significantly decreasing miR-21 values 2 d post therapy compared to non-responders (median miR-21 2−ΔΔCт: responders 0.73 [IQR 0.34], non-responders 1.53 [IQR 1.48];p = 0.0102). miR-210 did not show any significant difference between responders and non-responders (median miR-210 2−ΔΔCт: responders 0.74 [IQR 0.45], non-responders 0.99 [IQR 1.13];p = 0.8399). Kaplan–Meier curves demonstrated significantly shorter time to systemic progression for increased miR-21 (p = 0.0095) but not miR-210 (p = 0.7412), with events accumulating > 1 year post therapy in non-responders (median time to systemic progression 397 days).Conclusion: Increasing circulating miR-21 levels are associated with poor response and shorter time to systemic progression in HDR-BT-treated HCC. This proof-of-concept study provides a basis for further investigation of miR-21 as a prognostic biomarker and potential stratifier in future clinical trials of interventional oncology therapies.Trial registration:In this monocentric clinical study, we analyzed prospectively acquired data of 24 patients from the “ESTIMATE” patient cohort (Studiennummer: DRKS00010587, Deutsches Register Klinischer Studien). Ethical approval was provided by the ethics committee “Ethikkommission bei der LMU München” (reference number “17-346”) on June 20, 2017 and August 26, 2020.


  • Radiofrequency Ablation–Induced Tumor Growth Is Suppressed by MicroRNA-21 Inhibition in Murine Models of Intrahepatic Colorectal Carcinoma

    by Lukas Salvermoser, S. Nahum Goldberg, Flinn Laville, Aurelia Markezana, Matthias Stechele, Muneeb Ahmed, Moritz Wildgruber, Philipp M. Kazmierczak, Marianna Alunni-Fabbroni, Eithan Galun, et al.